Navigation Links
Neurobiological Technologies' CEO to Retire on December 31, 2008
Date:7/7/2008

EMERYVILLE, Calif., July 7 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that Paul E. Freiman, president and chief executive officer (CEO), has announced his intent to retire on December 31, 2008. The Company expects Mr. Freiman to continue to serve on the Board. Mr. Freiman is the former chief executive officer of Syntex Corporation of Palo Alto, California.

Mr. Freiman is retiring after 11 years of service to the company. "Paul's strong leadership has helped grow our company to where we have a Phase 3 program in a highly underserved acute ischemic stroke market and his contributions with XERECEPT(R) and Memantine to our organization will be long- lasting. We thank him for his dedicated service and wish him the best as he moves on to the next chapter in his life," said Abraham E. Cohen, NTI's chairman of the Board of Directors.

Mr. Freiman stated, "Since I stepped into the role of an interim CEO in 1997, I have enjoyed all aspects of my time at NTI. I remain committed to our principal product, Viprinex(TM), which may provide an extraordinary opportunity in the treatment of acute ischemic stroke. I have announced my intent so that the Board of Directors has sufficient time to thoughtfully identify my successor. I will direct our operations with vigor over the next six months and continue to be an active NTI director beyond my retirement."

A committee has been formed by the Board of Directors, headed by NTI director, William A. Fletcher, Chairman of Teva North America, to search for a new CEO and has engaged the services of a retained search firm.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc, (Nasdaq: '/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Neurobiological Technologies Reports Third Quarter Financial Results
2. Neurobiological Technologies Sets Date for Third Quarter Financial Results
3. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
5. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
6. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
7. Neurobiological Technologies Sets Date for Research and Development Day
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
9. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
10. Neurobiological Technologies Sets Date for Second Quarter Financial Results
11. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... -- Faced with increasing challenges such as costly treatments ... the global healthcare industry today is gradually transforming ... or significantly changing the course of a disease, ... medicine as a viable alternative. Regenerative ... with the potential to resolve unmet medical needs ...
(Date:7/27/2015)... 27, 2015 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ... commercializing products for the treatment of cancer, today provides ... it has closed a $1,000,000 unit offering private placement.  ... units of the Company at a price of $0.06 ... share and one common share purchase warrant.  Each whole ...
(Date:7/27/2015)... ... 2015 , ... Brady (NYSE:BRC), a global leader ... Ways to GHS Labels . This video provides useful information on how to ... effectively labeling chemical containers. , “With the fourth and final deadline for HazCom/GHS ...
(Date:7/27/2015)... ... July 27, 2015 , ... BlueInGreen® announced ... The venture will bring the world’s most efficient gas dissolution technology to all ... technologies to both the industrial and municipal markets. With offices located in Sarasota, ...
Breaking Biology Technology:Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5Quest PharmaTech Closes $1,000,000 Private Placement 2Brady Releases “3 Roads to GHS Labels” Video 2BlueInGreen Brings Water Treatment Technology to Florida 2
... Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... therapies, today announced that it will hold a ... and year-end financial results and provide a corporate ... Company,s lead product candidate.Jerry McMahon, Ph.D., chairman and ...
... NEW YORK, March 5 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... a letter from the Staff of The Nasdaq Stock ... compliance with Nasdaq Marketplace Rule 4310(c)(3), which requires the ... equity, or $35,000,000 market value of listed securities, or ...
... March 5 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... company focused on researching,developing, manufacturing and marketing ... the relevant provisions issued by the,Office of ... Finance,National Revenue Department in Liaoning Province and ...
Cached Biology Technology:Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12 2Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 2Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 3Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification 4
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... growth of several types of cancer cells lead to ... at Winship Cancer Institute of Emory University have discovered. ... that cancer cells tend to consume more glucose, or ... as the "Warburg effect," honoring discoverer Otto Warburg, a ...
... Like other users of microfluidic systems, National Institute ... faced with an annoying engineering problem: how to simply, ... devices to the external pumps and reservoirs delivering liquids ... randomly picked up two magnets and began playing with ...
... moa, a giant extinct bird, has revealed a new geological ... in the Proceedings of the National Academy of Sciences ... University of Adelaide has reconstructed a history of marine barriers, ... of years, using the first complete genetic history of the ...
Cached Biology News:Cancers' sweet tooth may be weakness 2Novel NIST connector uses magnets for leak-free microfluidic devices 2Extinct moa rewrites New Zealand's history 2
BD BioCoat Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
The F40 piston assembly is supplied as two assemblies to service one F40 pump of a BioLogic DuoFlow workstation....
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
... used as an internal standard for the ... mass spectrometry. 5-OxoETE is a polyunsaturated keto ... in human neutrophils. It stimulates cytosolic calcium ... 2 nM. 5-OxoETE selectively stimulates the migration ...
Biology Products: